Optogenetics restores partial vision in retinitis pigmentosa trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- A small optogenetics trial published Wednesday in the New England Journal of Medicine partially restored vision in patients with retinitis pigmentosa, a genetic disorder with no existing cure for most cases.
- Retinitis pigmentosa causes degeneration of the light-sensing cells in the retina and is typically diagnosed in childhood or early adolescence.
- Patients gradually lose peripheral and night vision and often become legally blind by young adulthood, with management limited to slowing degeneration and preserving remaining sight.
- Optogenetics — the technology recognized in this year's Nobel Prize — is now being tested as a potential therapeutic approach after peer-reviewed publication in NEJM.
Why it matters: For the majority of retinitis pigmentosa patients facing irreversible blindness with no cure beyond gene therapy for one specific mutation subset, a peer-reviewed NEJM report of partial vision restoration via optogenetics — a technology just recognized with a Nobel Prize — opens a tangible new research pathway where virtually none existed before.
Ask SkimNews
